HSP70 expression in skeletal muscle of patients with peripheral arterial occlusive disease.

Abstract

heat shock protein (HSP70) has been studied in the ischaemic myocardium and proven to provide protection against ischaemia. However, HSP70 in ischaemic skeletal muscle in patients with peripheral arterial occlusive disease (PAOD) has not been reported. thirty-four patients with PAOD (Fontaine's criteria: stage II: 15; III: 9 and IV: 10, respectively) and ten non-PAOD controls were enrolled in the study. Calf muscle samples were taken. HSP70 was quantitated by SDS-PAGE using ultrasensitive silver staining with reference to a series of standard HSP70, and HSP70 mRNA was estimated using RT-PCR. in comparison with the controls [median with range: 24.8 (14.1-35.6) ng in 2.5 microg total protein], HSP70 was increased significantly in PAOD [stage II: 93.1 (62.7-114.3); stage III: 110.1 (89.7-134.5) and stage IV: 77.4 (67.3-101.1)]. Similar results were obtained with HSP70 mRNA. HSP70 is increased in the ischaemic skeletal muscle in patients with PAOD, and HSP70 expression is different with regard to clinical stages, and the upregulation of HSP70 mRNA implies that the expression of HSP70 seems to be regulated at transcriptional level.